Canine Epithelial Thymic Tumors: Outcome in 28 Dogs Treated by Surgery

Area of Science:

• Veterinary Oncology
• Canine Neoplasia
• Thoracic Tumors

Background:

• Thymoma is a rare canine tumor, often presenting with space-occupying effects or paraneoplastic syndromes.
• Differentiating thymoma from mediastinal lymphoma is crucial for accurate diagnosis and treatment planning.
• Clinical signs of canine thymoma can be delayed, leading to late-stage diagnosis.

Purpose of the Study:

• To report the clinical experience with thymomas and thymic carcinomas in dogs.
• To evaluate prognostic factors and survival times for canine thymoma and thymic carcinoma.
• To highlight diagnostic and therapeutic strategies for these thoracic tumors.

Main Methods:

• Retrospective case series of 28 dogs with thymoma or thymic carcinoma.
• Diagnostic methods included computed tomography (CT), fine-needle aspirates, core biopsies, and flow cytometry.
• Treatment involved surgical excision, with adjuvant radiotherapy and/or chemotherapy considered.

Main Results:

• Median overall survival was 1173 days; median disease-free interval was 903 days.
• Thymic carcinoma cases showed significantly shorter disease-free intervals and survival times.
• Masaoka Stage III tumors were associated with poorer outcomes.

Conclusions:

• Complete surgical excision is the treatment of choice for canine thymoma.
• Adjuvant therapies may improve survival in incomplete excisions or thymic carcinomas.
• Prognosis is generally favorable with complete resection, but advanced stages and carcinoma subtype warrant closer monitoring.